Physician profile
Marc Feingold
NPI 1306805015
$1,344.08
in general payments reported to CMS, 2019-2025
15 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.94 · 2020: $84.80 · 2021: $118 · 2022: $53.03 · 2023: $255 · 2024: $345 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $509.86 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $290.39 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $151.93 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Sanofi Pasteur INC. | $84.48 | 2024-2025 | |
| Lilly USA, LLC | $68.85 | 2022-2025 | Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $58.49 | 2024-2025 | Nexletol |
| Abbott Laboratories | $37.55 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $31.82 | 2024-2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $20.97 | 2019 | |
| Phadia US INC. | $19.96 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $16.66 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $15.09 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.25 | 2023 | |
| Genentech USA, INC. | $11.97 | 2019 | |
| Pfizer INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Feingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.